In the fight to treat Covid-19 patients, much of the published research we’ve seen has focused on potential treatments for people with severe symptoms. Now though, there’s a new study that’s looking at how to repurpose existing medications to treat mild-to-moderate Covid-19 sufferers — and you can take part in it.
Led by the Duke Clinical Research Institute, this clinical trial called ACTIV-6 is looking into how three medications could alleviate common (and milder) Covid-19 symptoms, like fatigue, difficulty breathing, fever, cough, nausea, and body aches. The prescriptions in question include ivermectin, which usually treats parasitic infections; fluticasone, a steroid normally used for asthma sufferers; and fluvoxamine, which is often prescribed for depression. Scientists haven’t specified how each medication is targeting routine Covid-19 symptoms, but they show promise.
Researchers want to have over 15,000 participants in this study, with the hope that the results can serve as the basis for larger medical trials and hopefully a medicine rollout in the future. You can even receive a $100 gift card for your help! “Speeding enrollment in the ACTIV-6 study is of critical importance as the pandemic evolves and highly transmissible variants appear throughout the nation and around the world,” Susanna Naggie, MD, a principal investigator overseeing the study’s clinical coordination, said in a statement. “The study will yield valuable data on whether repurposed medications can help address the unmet public health need for people experiencing mild-to-moderate COVID-19 symptoms.”
There are only three requirements to join:
- You must be 30 years or older.
- You’ve tested positive for Covid-19 in the last 10 days.
- You’ve had at least two Covid-19 symptoms for seven days or less.
For those interested, signing up couldn’t be easier. You’ll just need to go to the study’s website to fill out some basic information or call 833-385-1880. Hopefully, you can be one of many people helping researchers figure out how to alleviate Covid-19 symptoms.